Health4 hours ago
EU Approves Tislelizumab for High-Risk Lung Cancer Patients
The European Commission (EC) has granted approval for tislelizumab (Tevimbra) as a combination treatment for adults with resectable non-small cell lung cancer (NSCLC) at high risk...